Lytix Biopharma AS (OSL:LYTIX)
Norway flag Norway · Delayed Price · Currency is NOK
8.60
-0.08 (-0.92%)
Jun 6, 2025, 4:25 PM CET

Lytix Biopharma AS Cash Flow Statement

Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Net Income
-89.01-94.27-87.9-56.07-48.08-42.09
Upgrade
Depreciation & Amortization
0.930.920.960.920.45-
Upgrade
Stock-Based Compensation
0.450.884.181.384.058.4
Upgrade
Other Operating Activities
-1.52-1.5-2.35-1.35-0.13-0
Upgrade
Change in Accounts Receivable
9.48-0.34-6.04-1.06-1.510.47
Upgrade
Change in Accounts Payable
20.7423.94-4.833.550.618.87
Upgrade
Operating Cash Flow
-58.93-70.37-95.97-52.63-44.61-24.35
Upgrade
Capital Expenditures
---0.05-0.15--
Upgrade
Investment in Securities
13.5123.1827.42-50.61--
Upgrade
Other Investing Activities
1.531.512.351.410.14-
Upgrade
Investing Cash Flow
15.0424.6929.73-49.360.14-
Upgrade
Long-Term Debt Repaid
--0.85-0.94-0.83-0.42-
Upgrade
Net Debt Issued (Repaid)
-0.83-0.85-0.94-0.83-0.42-
Upgrade
Issuance of Common Stock
161.3161.3-0.13225.2140
Upgrade
Other Financing Activities
-11.34-11.34-0-0.06-11.49-
Upgrade
Financing Cash Flow
149.13149.11-0.94-0.75213.340
Upgrade
Miscellaneous Cash Flow Adjustments
0----0-
Upgrade
Net Cash Flow
105.24103.43-67.19-102.73168.8315.65
Upgrade
Free Cash Flow
-58.93-70.37-96.02-52.78-44.61-24.35
Upgrade
Free Cash Flow Margin
-9691.78%-632.05%-2405.86%-478.47%-231.04%-597.62%
Upgrade
Free Cash Flow Per Share
--1.30-2.40-1.33-1.34-0.93
Upgrade
Cash Interest Paid
0.010.0100.060-
Upgrade
Levered Free Cash Flow
-25.14-34.62-66.3-36.49-26.43-8.74
Upgrade
Unlevered Free Cash Flow
-25.06-34.54-66.27-36.4-26.39-8.74
Upgrade
Change in Net Working Capital
-30.22-23.610.87-2.50.9-9.35
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.